Drug Eruption and Cutaneous Metastasis in a Patient with ALK-negative Anaplastic Large T-cell Lymphoma after Tislelizumab.

Australasian Journal of DermatologyEarly View CLINICAL LETTER Drug eruption and cutaneous metastasis in a patient with ALK-negative anaplastic large T-cell lymphoma after tislelizumab Ting Su MM, Ting Su MM orcid.org/0000-0001-8372-3324 Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaSearch for more papers by this authorXingbao Luan MM, Xingbao Luan MM Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaSearch for more papers by this authorYan Lu PhD, Yan Lu PhD orcid.org/0000-0001-7159-879X Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaSearch for more papers by this authorYang Xu PhD, Corresponding Author Yang Xu PhD [email protected] Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China Correspondence Yang Xu, Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu Province, China. Email: [email protected]Search for more papers by this author Ting Su MM, Ting Su MM orcid.org/0000-0001-8372-3324 Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaSearch for more papers by this authorXingbao Luan MM, Xingbao Luan MM Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaSearch for more papers by this authorYan Lu PhD, Yan Lu PhD orcid.org/0000-0001-7159-879X Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, ChinaSearch for more papers by this authorYang Xu PhD, Corresponding Author Yang Xu PhD [email protected] Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China Correspondence Yang Xu, Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu Province, China. Email: [email protected]Search for more papers by this author First published: 19 June 2024 https://doi.org/10.1111/ajd.14337Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Norimatsu Y, Akatsuka T, Matsuoka A, Hamada T, Mori I, Shiomi T, et al. Detection of TRAF1-ALK fusion in skin lesions of systemic ALK+ anaplastic large cell lymphoma initially involving the skin and the draining lymph node. J Dermatol. 2024; 51: 120–124. https://doi.org/10.1111/1346-8138.16981 10.1111/1346-8138.16981 CASWeb of Science®Google Scholar 2Gao Y, Hu S, Li R, Jin S, Liu F, Liu X, et al. Hyperprogression of cutaneous T cell lymphoma after anti-PD-1 treatment. JCI Insight. 2023; 8:e164793. https://doi.org/10.1172/jci.insight.164793 10.1172/jci.insight.164793 Web of Science®Google Scholar 3Watanabe T, Yamaguchi Y. Cutaneous manifestations associated with immune checkpoint inhibitors. Front Immunol. 2023; 14:1071983. https://doi.org/10.3389/fimmu.2023.1071983 10.3389/fimmu.2023.1071983 CASPubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation